Skip to main content

Luminex Q4 Revenues Rise 8.3 Percent, Net Loss Balloons 71 Percent

NEW YORK, Feb. 10 (GenomeWeb News) - Luminex yesterday reported that fourth-quarter revenue increased 8.3 percent to $9.1 million from $8.4 million in the year-ago quarter.

 

R&D spending for the three months ended Dec. 31, 2004, increased 13 percent to $908,000 from $807,000 for the same quarter in 2003.

 

Net loss in the current quarter surged 71 percent to $1.1 million from $643,000 in the year-ago quarter.

 

The company had $36 million in cash and cash equivalents on hand as of Dec. 31.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.